1. Long-term disease control by trabectedin in a patient with dedifferentiated liposarcoma
   Shogo Matsuda et al, 2020, Medicine CrossRef
2. What makes real world outcomes in soft tissue sarcomas? A mono-institutional trabectedin experience
   Guillaume Moriceau et al, 2015, Bulletin du Cancer CrossRef
3. A comprehensive review of the current evidence for trabectedin in advanced myxoid liposarcoma
   Tarek Assi et al, 2019, Cancer Treatment Reviews CrossRef
4. Trabectedin for Patients with Advanced Soft Tissue Sarcoma: A Non-Interventional, Prospective, Multicenter, Phase IV Trial
   Viktor Grünwald et al, 2022, Cancers CrossRef
5. Central venous access related adverse events after trabectedin infusions in soft tissue sarcoma patients; experience and management in a nationwide multi-center study
   Michiel C. Verboom et al, 2017, Clinical Sarcoma Research CrossRef
6. Do older and younger patients derive similar survival benefits from novel oncology drugs? A systematic review and meta-analysis
   Vanessa S Arciero et al, 2018, Age and Ageing CrossRef
7. Risk assessment of radio-chemotherapy in pediatric soft tissue sarcomas
   A. Abaza et al, 2015, Journal of Radiation Research and Applied Sciences CrossRef
8. Systemic Treatment of Soft Tissue Sarcomas in the Geriatric Population
   Mia C. Weiss, 2022, Current Treatment Options in Oncology CrossRef
9. The potential role of the extracellular matrix in the activity of trabectedin in UPS and L-sarcoma: evidences from a patient‐derived primary culture case series in tridimensional and zebrafish models
   Alessandro De Vita et al, 2021, Journal of Experimental & Clinical Cancer Research CrossRef
10. FAM83D acts as an oncogene by regulating cell cycle progression via multiple pathways in synovial sarcoma: a potential novel downstream target oncogene of anlotinib
    Zi-mei Liu et al, 2024, Discover Oncology CrossRef
11. Emerging therapies for adult soft tissue sarcoma
    Stefano Radaelli et al, 2014, Expert Review of Anticancer Therapy CrossRef
12. Efficacy and tolerability of trabectedin in elderly patients with sarcoma: subgroup analysis from a phase III, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma
    R.L. Jones et al, 2018, Annals of Oncology CrossRef